|
Name |
Penicibrocazine E
|
| Molecular Formula | C20H24N2O6S2 | |
| IUPAC Name* |
(1R,4R,5R,9R,11R,14R,15S,19S)-5,15-dihydroxy-1,11-bis(methylsulfanyl)-3,13-diazapentacyclo[11.7.0.03,11.04,9.014,19]icos-6-ene-2,8,12,18-tetrone
|
|
| SMILES |
CS[C@@]12C[C@H]3[C@@H](N1C(=O)[C@@]4(C[C@@H]5[C@@H](N4C2=O)[C@@H](C=CC5=O)O)SC)[C@H](CCC3=O)O
|
|
| InChI |
InChI=1S/C20H24N2O6S2/c1-29-19-7-9-11(23)3-5-13(25)15(9)21(19)18(28)20(30-2)8-10-12(24)4-6-14(26)16(10)22(20)17(19)27/h3,5,9-10,13-16,25-26H,4,6-8H2,1-2H3/t9-,10+,13+,14-,15+,16+,19+,20+/m0/s1
|
|
| InChIKey |
QOXQVMHGUNMPOZ-BHACCYINSA-N
|
|
| Synonyms |
Penicibrocazine E
|
|
| CAS | NA | |
| PubChem CID | 139583686 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 452.5 | ALogp: | -0.9 |
| HBD: | 2 | HBA: | 8 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 166.0 | Aromatic Rings: | 5 |
| Heavy Atoms: | 30 | QED Weighted: | 0.611 |
| Caco-2 Permeability: | -5.021 | MDCK Permeability: | 0.00001800 |
| Pgp-inhibitor: | 0.45 | Pgp-substrate: | 0.489 |
| Human Intestinal Absorption (HIA): | 0.282 | 20% Bioavailability (F20%): | 0.007 |
| 30% Bioavailability (F30%): | 0.049 |
| Blood-Brain-Barrier Penetration (BBB): | 0.001 | Plasma Protein Binding (PPB): | 59.93% |
| Volume Distribution (VD): | 0.353 | Fu: | 36.60% |
| CYP1A2-inhibitor: | 0.001 | CYP1A2-substrate: | 0.218 |
| CYP2C19-inhibitor: | 0.04 | CYP2C19-substrate: | 0.882 |
| CYP2C9-inhibitor: | 0.372 | CYP2C9-substrate: | 0.165 |
| CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0.049 |
| CYP3A4-inhibitor: | 0.138 | CYP3A4-substrate: | 0.974 |
| Clearance (CL): | 8.547 | Half-life (T1/2): | 0.937 |
| hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.162 |
| Drug-inuced Liver Injury (DILI): | 0.98 | AMES Toxicity: | 0.004 |
| Rat Oral Acute Toxicity: | 0.959 | Maximum Recommended Daily Dose: | 0.612 |
| Skin Sensitization: | 0.23 | Carcinogencity: | 0.297 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
| Respiratory Toxicity: | 0.001 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002661 | ![]() |
0.745 | D0I5DS | ![]() |
0.220 | ||
| ENC003671 | ![]() |
0.745 | D0D1SG | ![]() |
0.214 | ||
| ENC003673 | ![]() |
0.514 | D0IL7L | ![]() |
0.214 | ||
| ENC003573 | ![]() |
0.477 | D08PIQ | ![]() |
0.211 | ||
| ENC003809 | ![]() |
0.455 | D0V9DZ | ![]() |
0.211 | ||
| ENC003617 | ![]() |
0.454 | D0D2TN | ![]() |
0.211 | ||
| ENC000993 | ![]() |
0.309 | D0CZ1Q | ![]() |
0.211 | ||
| ENC006009 | ![]() |
0.287 | D04SFH | ![]() |
0.210 | ||
| ENC005509 | ![]() |
0.287 | D0Y7IU | ![]() |
0.209 | ||
| ENC003035 | ![]() |
0.277 | D04QNO | ![]() |
0.209 | ||